Opus Genetics (IRD) Share-based Compensation (2010 - 2026)
Opus Genetics (IRD) reported Share-based Compensation of $1.5 million for Q1 2026, up 60.35% year-over-year from $913000.0 in Q1 2025, and up 157.98% on a QoQ basis from -$2.5 million in Q4 2025.
Opus Genetics (IRD) has 17 years of Share-based Compensation data on file, last reported at $1.5 million in Q1 2026.
- Quarterly Share-based Compensation rose 60.35% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $651000.0 (down 86.66% YoY) and the FY2025 annual result came in at $100000.0, down 97.03% from the prior year.
- Share-based Compensation improved to $1.5 million in Q1 2026 per IRD's latest filing, from -$2.5 million in the prior quarter.
- Across five years, Share-based Compensation topped out at $247.0 million in Q1 2023 and bottomed at -$2.5 million in Q4 2025.
- The 5-year median for Share-based Compensation is $758500.0 (2023), against an average of $16.0 million.
- The widest annual swing landed in 2022, when Share-based Compensation tumbled 356.58%; it then surged 55405.62% in 2023.
- Tracing IRD's Share-based Compensation over 5 years: stood at -$1.2 million in 2022, then jumped by 157.85% to $711000.0 in 2023, then jumped by 344.73% to $3.2 million in 2024, then slumped by 179.85% to -$2.5 million in 2025, then surged by 157.98% to $1.5 million in 2026.
- Per Business Quant, the three latest IRD Share-based Compensation figures stand at $1.5 million (Q1 2026), -$2.5 million (Q4 2025), and $816000.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Share-based Compensation (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 892,057.00 |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 305,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 166.40 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 257.40 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 70.15 Mn |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - | 1.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.46 Mn |
| Mar 31, 2026 | 1.46 Mn |
| Dec 31, 2025 | -2.53 Mn |
| Dec 31, 2025 | -2.53 Mn |
| Sep 30, 2025 | 816,000.00 |
| Sep 30, 2025 | 816,000.00 |
| Jun 30, 2025 | 896,000.00 |
| Jun 30, 2025 | 896,000.00 |
| Mar 31, 2025 | 913,000.00 |
| Mar 31, 2025 | 913,000.00 |
| Dec 31, 2024 | 3.16 Mn |
| Dec 31, 2024 | 3.16 Mn |
| Jun 30, 2024 | 806,000.00 |
| Jun 30, 2024 | 806,000.00 |
| Mar 31, 2024 | 245,000.00 |
| Mar 31, 2024 | 245,000.00 |
| Dec 31, 2023 | 711,000.00 |
| Dec 31, 2023 | 711,000.00 |
| Sep 30, 2023 | 573,000.00 |
| Sep 30, 2023 | 573,000.00 |
| Jun 30, 2023 | 1.42 Mn |
| Jun 30, 2023 | 1.42 Mn |
| Mar 31, 2023 | 247.00 Mn |
| Mar 31, 2023 | 247.00 Mn |
| Dec 31, 2022 | -1.23 Mn |
| Dec 31, 2022 | -1.23 Mn |
| Sep 30, 2022 | 99,000.00 |
| Sep 30, 2022 | 99,000.00 |
| Jun 30, 2022 | 445,000.00 |
| Jun 30, 2022 | 445,000.00 |
| Mar 31, 2022 | 445,000.00 |
| Mar 31, 2022 | 445,000.00 |
| Dec 31, 2021 | 479,000.00 |
| Dec 31, 2021 | 479,000.00 |
| Sep 30, 2021 | 26,000.00 |
| Sep 30, 2021 | 26,000.00 |
| Jun 30, 2021 | 29,000.00 |
| Jun 30, 2021 | 29,000.00 |
| Mar 31, 2021 | 494,000.00 |
| Mar 31, 2021 | 494,000.00 |
| Dec 31, 2020 | 513,000.00 |
| Dec 31, 2020 | 513,000.00 |
| Sep 30, 2020 | 616,000.00 |
| Sep 30, 2020 | 616,000.00 |
| Jun 30, 2020 | 316,000.00 |
| Jun 30, 2020 | 316,000.00 |
| Mar 31, 2020 | 61,000.00 |
| Mar 31, 2020 | 61,000.00 |
| Dec 31, 2019 | -71,348.00 |
| Dec 31, 2019 | -71,348.00 |
| Sep 30, 2019 | 90,695.00 |
| Sep 30, 2019 | 90,695.00 |
| Jun 30, 2019 | 127,653.00 |
| Jun 30, 2019 | 127,653.00 |
| Mar 31, 2019 | 161,000.00 |
| Mar 31, 2019 | 161,000.00 |
| Dec 31, 2018 | -822,560.00 |
| Dec 31, 2018 | -822,560.00 |
| Sep 30, 2018 | 281,482.00 |
| Sep 30, 2018 | 281,482.00 |
| Jun 30, 2018 | 267,151.00 |
| Jun 30, 2018 | 267,151.00 |
| Mar 31, 2018 | 296,577.00 |
| Mar 31, 2018 | 296,577.00 |
| Dec 31, 2017 | 254,161.00 |
| Dec 31, 2017 | 254,161.00 |
| Sep 30, 2017 | 227,614.00 |
| Sep 30, 2017 | 227,614.00 |
| Jun 30, 2017 | 288,065.00 |
| Jun 30, 2017 | 288,065.00 |
| Mar 31, 2017 | 274,327.00 |
| Mar 31, 2017 | 274,327.00 |
| Dec 31, 2016 | 1.31 Mn |
| Dec 31, 2016 | 1.31 Mn |
| Sep 30, 2016 | 369,402.00 |
| Sep 30, 2016 | 369,402.00 |
| Jun 30, 2016 | 351,176.00 |
| Jun 30, 2016 | 351,176.00 |
| Mar 31, 2016 | 343,011.00 |
| Mar 31, 2016 | 343,011.00 |
| Dec 31, 2015 | 935,679.00 |
| Dec 31, 2015 | 935,679.00 |
| Sep 30, 2015 | 225,316.00 |
| Sep 30, 2015 | 225,316.00 |
| Jun 30, 2015 | 271,966.00 |
| Jun 30, 2015 | 271,966.00 |
| Mar 31, 2015 | 56,250.00 |
| Mar 31, 2015 | 56,250.00 |
| Dec 31, 2014 | 184,736.00 |
| Dec 31, 2014 | 184,736.00 |
| Sep 30, 2014 | 163,191.00 |
| Sep 30, 2014 | 163,191.00 |
| Jun 30, 2014 | 132,518.00 |
| Jun 30, 2014 | 132,518.00 |
| Mar 31, 2014 | 128,350.00 |
| Mar 31, 2014 | 128,350.00 |
| Dec 31, 2013 | 71,391.00 |
| Dec 31, 2013 | 71,391.00 |
| Sep 30, 2013 | 67,715.00 |
| Sep 30, 2013 | 67,715.00 |
| Jun 30, 2013 | 54,371.00 |
| Jun 30, 2013 | 54,371.00 |
| Mar 31, 2013 | 371,951.00 |
| Mar 31, 2013 | 371,951.00 |
| Dec 31, 2012 | 28,450.00 |
| Dec 31, 2012 | 28,450.00 |
| Sep 30, 2012 | 60,611.00 |
| Sep 30, 2012 | 60,611.00 |
| Jun 30, 2012 | 50,752.00 |
| Jun 30, 2012 | 50,752.00 |
| Mar 31, 2012 | 91,174.00 |
| Mar 31, 2012 | 91,174.00 |
| Dec 31, 2011 | 125,352.00 |
| Dec 31, 2011 | 125,352.00 |
| Sep 30, 2011 | 141,089.00 |
| Sep 30, 2011 | 141,089.00 |
| Jun 30, 2011 | 170,178.00 |
| Jun 30, 2011 | 170,178.00 |
| Mar 31, 2011 | 201,988.00 |
| Mar 31, 2011 | 201,988.00 |
| Dec 31, 2010 | -1.08 Mn |
| Dec 31, 2010 | -1.08 Mn |
| Sep 30, 2010 | 1.34 Mn |
| Sep 30, 2010 | 1.34 Mn |